Yenssen Biotech seeks global distributors for CE- and FDA-cleared wound care products

By AI, Created 5:06 PM UTC, May 18, 2026, /AGP/ – Yenssen Biotech is recruiting medical device distributors across North America, Europe, the Middle East, Southeast Asia and Latin America for three product lines that meet CE marking and FDA registration standards. The move targets growing demand for advanced wound care, oral ulcer treatment and bone repair products.

Why it matters: - Yenssen Biotech is trying to widen international sales for products aimed at hospitals, wound care centers, dental clinics, pharmacies and specialty care channels. - The company is positioning CE-marked and FDA-registered products for markets where buyers want clinically backed alternatives with lower cost pressure. - The global advanced wound care market is projected to top USD 15 billion by 2028, driven by aging populations, diabetes and chronic wounds.

What happened: - Yenssen Biotech announced an expanded global distributor recruitment effort on May 15, 2026. - The company is seeking qualified medical device distributors in North America, Europe, the Middle East, Southeast Asia and Latin America. - The partnership push covers three product lines: the Dermlin wound healing series, Ulceloocin oral ulcer patch and a bone defect repair portfolio. - Yenssen Biotech was founded in 2003 and is headquartered in Jiangyin, Jiangsu Province.

The details: - Dermlin is an inorganic, antibiotic-free advanced wound dressing built on a nano-porous granule formulation. - Dermlin is available in four forms: powder, paste, powder spray and dressing. - Dermlin is clinically indicated for surgical incisions, burns, abrasions, diabetic foot ulcers, venous stasis ulcers, pressure ulcers and other acute and chronic wounds. - The product is designed to neutralize acidic exudate, help prevent secondary infection and accelerate epithelial cell proliferation. - Ulceloocin is a dissolvable, hormone-free ulcer patch for mouth ulcers, canker sores and oral mucosal lesions. - Ulceloocin adheres to the lesion site without binding agents and dissolves naturally during healing. - The bone defect repair line uses biological microstructures to support osteoinduction and osteoconduction. - The biodegradable scaffolds are intended for orthopedic, dental and maxillofacial reconstructive applications. - Yenssen Biotech says the bone repair line has documented biological safety data supporting clinical use. - The company says Dermlin, Ulceloocin and the bone repair portfolio meet CE marking and FDA registration standards. - Yenssen Biotech operates a 45,000-plus-square-foot GMP-standard production facility, a dedicated R&D laboratory and a central inspection lab. - The company is a Chinese National Key Center for Class I, II and III medical devices.

Between the lines: - Yenssen Biotech is broadening beyond wound care to build a more complete portfolio for distributors that serve multiple clinical channels. - The product mix suggests a sales strategy aimed at cross-selling into medical, dental and home-care networks rather than relying on a single category. - The announcement leans on manufacturing scale, regulatory status and training support to make the distributor pitch more competitive. - Yenssen Biotech says it supports partners with local medical device registration help, co-funded marketing, product and clinical training, OEM and private label options, and clinical case studies.

What’s next: - Interested distributors in wound care, dermatology, surgical supplies, dental, orthopedic, home healthcare and long-term care channels are encouraged to apply. - Yenssen Biotech will likely use the recruitment campaign to expand its footprint in markets where regulatory readiness and local channel access are critical. - The company already serves customers in more than 30 countries, giving the distributor push an existing base for further international growth.

The bottom line: - Yenssen Biotech is using regulatory clearance, manufacturing capacity and a multi-category product lineup to court global distributors and push further into advanced wound care and adjacent markets.